Francisco J. Esteva

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Yoichi Nagata, Keng‐Hsueh Lan, Xiaoyan Zhou et al. · Cancer Cell · 2004 · 1.9K citations · Full text

Medicine, Cancer Biology, Oncology +14

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

Catharine M. Sturgeon, Michael J. Duffy, Ulf‐Håkan Stenman et al. · Clinical Chemistry · 2008 · 1.1K citations

Medicine, Oncology, Urology +17

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · Journal of Clinical Oncology · 2018 · 1.1K citations

Medicine, Oncology, Pharmacology +14

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · New England Journal of Medicine · 2019 · 841 citations · Full text

Medicine, Oncology, Pharmacology +14

Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells

Rita Nahta, Linda X.H. Yuan, Bing Zhang et al. · Cancer Research · 2005 · 801 citations

Medicine, Cancer Biology, Oncology +17